image credit: Unsplash

COVID-19 Nanoparticle Vaccine Elicits High Levels of Protective Antibodies in Mice

There are currently hundreds of COVID-19 vaccine candidates in development around the world. Some of the challenges facing them are the requirement of large doses, complex manufacturing, and cold-chain shipping and storage. An ultrapotent vaccine that is safe, effective at low doses, simple to produce, and stable outside of a freezer could enable vaccination against COVID-19 on a global scale. Now, a team of scientists at the University of Washington School of Medicine (UW Medicine) in Seattle report data on an innovative nanoparticle vaccine candidate that produces virus-neutralizing antibodies in mice at levels ten-times greater than is seen in people who have recovered from COVID-19 infections.

Read More on Genetic Engineering and Biotechnology News